Skip to content

Epizyme target upped to $22 by Citi

June 15, 2017

Citi raised its price target on Epizyme (NASDAQ: EPZM) to $22.00 (from $20.00) while maintaining a Buy rating after Tazemetostat data showed a strong response in follicular lymphoma patients with the EZH2 mutation and activity in other indications.

Analyst Robyn Karnauskas think the EZH2 MT data supports accelerated approval. In other indications, combination therapies will be the way forward, in the firm’s view.

“We expect clarity on regulatory strategy after the co. meets w/ the FDA in 2H’17,” she said. “The drug appears to be safe across all groups.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: